Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/11484
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKiyoshi Kikuchien_US
dc.contributor.authorHisaaki Uchikadoen_US
dc.contributor.authorNaoki Miuraen_US
dc.contributor.authorYoko Morimotoen_US
dc.contributor.authorTakashi Itoen_US
dc.contributor.authorSalunya Tancharoenen_US
dc.contributor.authorKei Miyataen_US
dc.contributor.authorRokudai Sakamotoen_US
dc.contributor.authorChiemi Kikuchien_US
dc.contributor.authorNarumi Iidaen_US
dc.contributor.authorNaoto Shiomien_US
dc.contributor.authorTerukazu Kuramotoen_US
dc.contributor.authorNaohisa Miyagien_US
dc.contributor.authorKo Ichi Kawaharaen_US
dc.contributor.otherYame General Hospitalen_US
dc.contributor.otherKurume University School of Medicineen_US
dc.contributor.otherKagoshima University Faculty of Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKagoshima Universityen_US
dc.contributor.otherNishida Koutoku Hospitalen_US
dc.contributor.otherKohjin Co., Ltd.en_US
dc.contributor.otherSaiseikai Shiga Hospitalen_US
dc.contributor.otherOmuta City General Hospitalen_US
dc.contributor.otherOsaka Institute of Technologyen_US
dc.date.accessioned2018-05-03T08:00:49Z-
dc.date.available2018-05-03T08:00:49Z-
dc.date.issued2011-09-01en_US
dc.identifier.citationExperimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-770en_US
dc.identifier.issn17921015en_US
dc.identifier.issn17920981en_US
dc.identifier.other2-s2.0-79960267925en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960267925&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/11484-
dc.description.abstractHistorically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB1 plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960267925&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleHMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)en_US
dc.typeReviewen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.3892/etm.2011.310en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.